Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06395506 · ClinicalTrials.gov registry record · NA

THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation

A NA study of Breast Cancer and Breast Cancer Female, sponsored by The University of Texas Medical Branch, Galveston.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT06395506 is a NA study of Breast Cancer and Breast Cancer Female that is actively recruiting participants, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 60 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06395506, a NA study of Breast Cancer and Breast Cancer Female, is actively recruiting participants, sponsored by The University of Texas Medical Branch, Galveston.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The study's purpose is to evaluate whether creatine supplementation can help breast cancer survivors respond quicker to exercise by improving strength, endurance, and body composition. We are seeking to compare information collected from healthy woman of the same age who have never had breast cancer to those participants who have had breast cancer and undergone chemotherapy treatment.

Interventions

  • DIETARY_SUPPLEMENT Creatine

Study Locations (1)

Texas

  • The University of Texas Medical Branch, Galveston - Galveston

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-10-29
Est. Completion 2028-05-31
Phase NA

What the Registry Record Tells You About NCT06395506

The ClinicalTrials.gov registry entry for NCT06395506 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Creatine is the first listed.

NCT06395506 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06395506 about?

NCT06395506 is a clinical study titled "THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation". The study's purpose is to evaluate whether creatine supplementation can help breast cancer survivors respond quicker to exercise by improving strength, endurance, and body composition. We are seeking to compare information collected from healthy woman of the same age who have never had breast cancer...

What is the current status of trial NCT06395506?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2024-10-29. Estimated completion is 2028-05-31.

What conditions does trial NCT06395506 study?

This clinical trial studies the following conditions: Breast Cancer, Breast Cancer Female, Muscle Weakness.

What interventions are being tested in trial NCT06395506?

The interventions under investigation include: Creatine (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06395506?

This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06395506 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.